Collaborations

Cardiovascular discovery collaboration signed with DMI BioSciences

Published in Heart Disease Weekly, April 4th, 2004

Biosite Incorporated (BSTE), a provider of novel, rapid medical diagnostics, announced that it has entered into a license and collaboration agreement with DMI BioSciences, Inc., under which Biosite intends to perform antibody development and marker validation of cysteinylated albumin (cys-albumin), a biomarker that is elevated in blood when a patient is undergoing ischemia.

Ischemia is an imbalance between oxygen supply and demand that leads to oxygen deficiency in tissues such as the heart. The American Heart Association estimates that 3 to 4 million Americans have ischemic episodes without even knowing it.

Under the terms of the agreement, Biosite...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Source: Heart Disease Weekly (2004-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry